PharmaCyte Biotech Inc. (PMCB): Price and Financial Metrics

PharmaCyte Biotech Inc. (PMCB): $2.37

0.07 (-2.87%)

POWR Rating

Component Grades

Momentum

F

Stability

C

Sentiment

Quality

C

Add PMCB to Watchlist
Sign Up

Industry: Biotech

Industry

F

Ranked

#60 of 390

in industry

PMCB Price/Volume Stats

Current price $2.37 52-week high $3.23
Prev. close $2.44 52-week low $1.92
Day low $2.29 Volume 34,500
Day high $2.50 Avg. volume 26,118
50-day MA $2.16 Dividend yield N/A
200-day MA $2.34 Market Cap 20.06M

PMCB Stock Price Chart Interactive Chart >


PharmaCyte Biotech Inc. (PMCB) Company Bio


PharmaCyte Biotech, Inc. (PharmaCyte) is a biotechnology company developing cellular therapies for cancer and diabetes based upon a proprietary cellulose-based live cell encapsulation technology known as “Cell-in-a-Box®.” This technology will be used as a platform upon which therapies for several types of cancer and diabetes are being developed.


PMCB Latest News Stream


Event/Time News Detail
Loading, please wait...

PMCB Latest Social Stream


Loading social stream, please wait...

View Full PMCB Social Stream

Latest PMCB News From Around the Web

Below are the latest news stories about PHARMACYTE BIOTECH INC that investors may wish to consider to help them evaluate PMCB as an investment opportunity.

PMCB Stock Earnings: PharmaCyte Biotech Reported Results for Q2 2024

PharmaCyte Biotech just reported results for the second quarter of 2024.

InvestorPlace Earnings on InvestorPlace | December 18, 2023

PharmaCyte Biotech Acquires $5 Million Stake in Emerging Women’s Health Innovator Femasys, Inc.

LAS VEGAS, November 15, 2023--PharmaCyte Biotech, Inc. (Nasdaq: PMCB) ("PharmaCyte" or the "Company") announces it has made a $5 million investment in Femasys, Inc. (Nasdaq:FEMY) ("Femasys"), a biomedical company focused on meeting significant unmet needs for women worldwide. Femasys offers a broad portfolio of in-office, accessible solutions, including a lead late-stage product candidate and innovative therapeutic and diagnostic products. This is the Company’s first investment in externally dev

Yahoo | November 15, 2023

Femasys Inc. Secures Additional Financing with Strategic Investment from Investors led by PharmaCyte Biotech

- $6.85 million upfront investment provides $23 million total cash runway into second half 2025 - - Financing allows for focused commercial team to bring Femasys’ infertility-related products to women in the U.S. - - Additional financing supports the advancement of Femasys’ lead product candidate, FemBloc® for permanent birth control, to initial clinical data readout - ATLANTA, Nov. 15, 2023 (GLOBE NEWSWIRE) -- Femasys Inc. (NASDAQ: FEMY), a biomedical company focused on meeting significant unme

Yahoo | November 15, 2023

PharmaCyte Biotech Provides Corporate Update on Cell-in-a-Box Technology

LAS VEGAS, October 31, 2023--PharmaCyte Biotech, Inc. (Nasdaq: PMCB) ("PharmaCyte" or the "Company") provides an update on its investigation of its Cell-in-a-Box technology and initial next steps in development. Following a comprehensive scientific review of amassed data, the Company is in the process of requesting a meeting with the U.S. Food and Drug Administration (FDA) for guidance on further development of the technology. The meeting is expected to occur during the first quarter of 2024. In

Yahoo | October 31, 2023

PharmaCyte Biotech Announces Final Results of Tender Offer

LAS VEGAS, June 15, 2023--PharmaCyte Biotech, Inc. (Nasdaq: PMCB) ("PharmaCyte" or the "Company") today announces the final results of its previously announced tender offer to acquire up to 7,750,000 million shares of the Company’s common stock, par value $0.001 per share, at a price of $3.25 per share in cash, less any applicable withholding taxes and without interest. The tender offer expired one minute after 11:59 p.m. on June 9, 2023, and was funded entirely through the Company’s cash on han

Yahoo | June 15, 2023

Read More 'PMCB' Stories Here

PMCB Price Returns

1-mo 12.86%
3-mo 9.72%
6-mo 12.86%
1-year -16.84%
3-year -90.87%
5-year -96.75%
YTD 9.72%
2023 -26.28%
2022 17.20%
2021 -75.12%
2020 -83.46%
2019 9.46%

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!